|  |
| --- |
| **MONITORING SITE VISIT CHECKLIST AND REPORT** |

|  |  |
| --- | --- |
| **CLINICAL TRIAL DETAILS** | |
| Protocol Title |  |
| Clinical Trials Registry ID/number: |  |
| Site Name |  |
| Site Investigator Name |  |
| Monitor Name |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **VISIT SUMMARY** | | | |
| Visit Date *(MM/DD/YYYY)* |  | | |
| Type of Visit | RMV  *(check the appropriate option)* | 3-5 enrolled participants |  |
| 20-25 enrolled participants |  |
| 90-100 enrolled participants |  |
| All participants enrolled |  |
| Unscheduled /FCV  *(write cause)* |  | |
| Study Personnel present during the visit | **Name** | **Title** | |
|  |  | |
|  |  | |
|  |  | |
|  |  | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **FACILITIES / STAFF** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| Compliance with protocol, study procedures and SOPs |  |  |  |  |
| Was the staff properly trained for the study? |  |  |  |
| Is the investigator properly supervising the personnel? |  |  |  |
| Has any staff or facility/work area change since last visit been properly recorded /updated? |  |  |  |
| Delegation log and training log complete and in accordance with qualifications and training? |  |  |  |
| Are facilities adequate? |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PARTICIPANTS VERIFICATION** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| Compliance with protocol? |  |  |  |  |
| Compliance with study procedures and SOPs |  |  |  |
| Recruitment on schedule? |  |  |  |
| Screening and enrolment log completed and update |  |  |  |
| Subject eligibility confirmed? |  |  |  |
| Medical record of enrolled participants references the study and indicates that the participants is receiving and IP? |  |  |  |
| Participant Information Leaflet and Informed Consent Form: | | | |  |
| * Current version used * Dated * Signed * Filed |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| HIV testing information leaflet and informed consent form | | | |  |
| * Current version used * Dated * Signed * Filed |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| Informed Consent Form for storage and use of your samples and data | | | |  |
| * Current version used * Dated * Signed * Filed |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| Informed consent form for the use of blood samples for genetic testing | | | |  |
| * Current version used * Dated * Signed * Filed |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| Has/Have there been any subject(s) lost to follow-up since the last monitoring visit report? |  |  |  |  |
| If withdrawals, are they during the first 8 weeks (while de IP are provided)? |  |  |  |
| If yes, are withdrawn subjects documented? |  |  |  |
| Has/Have there been any subject(s) discontinued from treatment or from the clinical trial? |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **CRF REVIEW** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| *A comparison between source documents to data listings entered into the CRF will be made. If >5% of data variables are incorrect, a second 10% random sample* | | | | |
| CRF reviewed |  |  |  |  |
| * 1 * 2 * 9 * 11 |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| Are CRFs complete? |  |  |  |  |
| Is data accurate and backed up with source documents? |  |  |  |
| CRF adhere to the protocol for procedures and assessment related to:   * study endpoints * protocol-required safety assessment * evaluation, documentation and reporting of SAE, SUSAR, significant safety issues, participants deaths, and withdrawals related to AE |  |  |  |
| Documentation and reporting of serious breaches meet the principles of ALCOA, plus complete and traceable |  |  |  |
| If paper CRF used, is there a delay entering data on REDCAP? |  |  |  |  |
| If paper CRF used, is there any discrepancy between paper CRF and REDCAP CRF? |  |  |  |
| CRF reviewed if 10% of additional random sample |  |  |  |  |
| * 1 * 2 * 9 * 11 |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| Are CRFs complete? |  |  |  |  |
| Is data accurate and backed up with source documents? |  |  |  |
| CRF adhere to the protocol for procedures and assessment related to:   * study endpoints * protocol-required safety assessment * evaluation, documentation and reporting of SAE, SUSAR, significant safety issues, participants deaths, and withdrawals related to AE |  |  |  |
| Documentation and reporting of serious breaches meet the principles of ALCOA, plus complete and traceable |  |  |  |
| If paper CRF used, is there a delay entering data on REDCAP? |  |  |  |
| If paper CRF used, is there any discrepancy between paper CRF and REDCAP CRF? |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SAFETY VIGILANCE** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| Any SAEs since last visit? |  |  |  |  |
| Have all SAE been appropriately reported? |  |  |  |
| Has the blind been maintained? |  |  |  |
| Were any unreported SAEs/significant safety issues discovered? |  |  |  |
| Are there any participants deaths or withdrawals related to AE? |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **ISF REVIEW** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| Was the Investigator ISF reviewed during this visit? |  |  |  |  |
| Signed protocol, amendments and revisions and CRF |  |  |  |
| Investigators brochure |  |  |  |
| Package inserts |  |  |  |
| IRB/IEC approval and versions of:   * Protocol * Participant information leaflet and informed consent form * Informed consent form for storage and use of your samples and date * HIV testing informant leaflet and informed consent form * Informed consent form for the use of blood samples for genetic testing |  |  |  |
| Regulatory approval and versions of:   * Protocol * Participant information leaflet and informed consent form * Informed consent form for storage and use of your samples and date * HIV testing informant leaflet and informed consent form * Informed consent form for the use of blood samples for genetic testing |  |  |  |
| Financial aspects of the trial |  |  |  |
| Insurance statement |  |  |  |
| Signed agreement between involved parties |  |  |  |
| Curriculum vitae of investigator(s) and sub-investigator(s) |  |  |  |
| Safety reporting to the sponsor |  |  |  |
| Safety reporting to the IRB |  |  |  |
| SUSAR |  |  |  |
| Shipping records of investigational products and trial-related products |  |  |  |
| Instruction for handling of investigational product (IP) and trial-related materials |  |  |  |
| Normal value(s)/ranges for procedures included in the protocol |  |  |  |
| Medical/laboratory/technical procedures/tests |  |  |  |
| Certificates of analysis of IP shipped |  |  |  |
| Decoding procedures for blinded trials |  |  |  |
| Delegation log |  |  |  |
| Training log |  |  |  |
| Communication between team members |  |  |  |
| Agreements/contracts -executed |  |  |  |
| Source documents |  |  |  |
| Interim or annual reports to IRB/IEC and authority(ies) |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **INVESTIGATIONAL PRODUCT** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| Was a pharmacy visit conducted? |  |  |  |  |
| Are all IPs correctly stored, dispensed and accounted? |  |  |  |
| Do the expiry dates of IP(s) remain compatible with the trial duration? |  |  |  |
| Are there sufficient IP supplies available for continuation of the trial? |  |  |  |
| Disposition of unused IP at the trial sites complies with applicable regulatory requirement(s) |  |  |  |
| Receipt, use and return of IP at the trial site is controlled and documented |  |  |  |  |
| Participants are provided with necessary instruction on properly using, handling, storing, and returning the IP |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **LABORATORY + DIAGNOSTIC SAMPLES** | **Yes** | **No** | **N/A** | **Action items/issues comments** |
| Are the labelling, storage and shipment of laboratory specimen/diagnostic material adequate? |  |  |  |  |
| Is record of sample’s tracking updated? |  |  |  |

|  |  |  |
| --- | --- | --- |
| **SUMMARY OF FINDINGS**  **IN RMV OR ACCORDING TO CENTRAL MONITORING** | | |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |
| **Finding:** | **Date detected** | |
|  |  | |
| **Corrective measure:** | **Resolution** | |
|  | Favourable |  |
| Unfavourable |  |
| Date: |  |

|  |  |
| --- | --- |
| **RECOMMENDATIONS OF MONITOR *(MARK)*** | |
|  | No action needed- study conduct is compliant with regulations, protocol and regulatory/IRB requirements. |
|  | No action required, but visit site again in \_\_\_\_\_\_\_\_ weeks to ensure corrections have been made. |
|  | Action required: investigator is noncompliant, schedule review meeting. |
|  | Action required: terminate study at site |

|  |  |
| --- | --- |
| **SIGNATURE AND DATE** | |
| **MONITOR** | **PRINCIPAL INVESTIGATOR** |
|  |  |